Dali Pharmaceutical Co., Ltd (China)

Dali Pharmaceutical Co., Ltd is a pharmaceutical company located in Dali, Yunnan Province, China. The company was established in October 1996 and became a foreign-invested joint-stock company in January 2008. It is ranked among the top 50 traditional Chinese medicine companies in China and is the 72nd largest enterprise in Yunnan Province. Dali Pharmaceutical is also listed on the Shanghai Stock Exchange, with the stock code 603963. The company specializes in the research and production of Chinese and Western medicine injections. Its main products include Xingnaojing Injection, Canmai Injection, Huangqi Injection, Liangjunmasu Injection, and Baoerli Injection. The company has obtained various certifications, including the national drug GMP certification and multiple patents. Dali Pharmaceutical has established research centers in collaboration with Zhejiang University and Dali University, and has formed long-term cooperative relationships with several universities for teaching and practical training purposes. The company has received numerous awards and honors, including the National May 1st Labor Medal and recognition as an innovative enterprise in Yunnan Province. Dali Pharmaceutical has over 300 employees, with a significant number holding bachelor's or higher degrees. The company has established a comprehensive management system and quality control system, and its marketing center is located in Kunming, Yunnan Province. Dali Pharmaceutical is committed to creating value for the country, the company, and patients, and strives to maintain high-quality standards in its operations.